Dr. Douglas Gnepp Joins CBLPath as Medical Director of Head and Neck Pathology


RYE BROOK, NY--(Marketwired - Feb 4, 2014) -  Focusing on the continued enhancement of its leading Head and Neck Pathology Program, CBLPath, a Sonic Healthcare USA laboratory, is pleased to announce the addition of Douglas Gnepp, M.D. as Medical Director, Head and Neck Program. He will primarily be responsible for the direction, operation and quality management of the Head and Neck Program.

Since 1991, Dr. Gnepp has served as Professor of Pathology at Brown University in Providence, R.I. and as Pathologist in the Department of Pathology of Rhode Island Hospital in Providence, R.I. He was awarded an Honorary Master of Arts degree from Brown University, Providence, R.I. in 1993 and earned is M.D. from Duke University, Durham, N.C. in 1974.

Certified by the American Board of Pathology as an Anatomic Pathologist, Dr. Gnepp was listed in Best Doctors in America, 2013; Cambridge Who's Who, 2009-2010; recognized as an Honorary Fellow of the American Academy of Oral and Maxillofacial Pathology and named in America's Top Pathologists by Consumers' Research Council of America, 2009.

"CBL Path is excited to have a physician of Dr. Gnepp's caliber join our company," said Dr. Carlos Urmacher, Co-CEO and Chief Medical Officer of CBLPath. "The addition of Dr. Gnepp will serve to further enhance our Head and Neck Program."

Dr. Gnepp's expertise in the area of histopathology complements the expertise of CBLPath's cytopathology department, led by Madeline Vazquez, M.D, Chief of Cytopathology. Dr. Vazquez is certified by the American Board of Pathology in Anatomic Pathology and leads CBLPath's world-class thyroid cytopathology program, which has one of the lowest indeterminate rates for the interpretation of thyroid fine needle aspirate biopsies in the United States.

CBLPath's leading Head and Neck Pathology program provides comprehensive cytopathology and histopathology services in the areas of thyroid, oral, ophthalmic pathology, dermatopathology, hematopathology, and gastrointestinal pathology. With a comprehensive test menu including immunohistochemistry, fluorescence in situ hybridization, flow cytometry, cancer cytogenetics and advanced molecular testing, CBLPath offers complete diagnostic, prognostic and theranostic testing delivering personalized medicine and effective patient care.

For more information on CBLPath's Head and Neck Program, please contact Client Services at 877.225.7284 or ContactUs@CBLPath.com. To see a comprehensive list of the company's testing services, visit www.CBLPath.com.

About CBLPath
CBLPath, a Sonic Healthcare USA laboratory, is a leading pathology services provider, combining anatomic pathology with advanced molecular diagnostics, esoteric testing and digital pathology. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. We integrate comprehensive diagnostic, prognostic and theranostic testing to deliver personalized medicine and we provide our subspecialty physician clients timely, accurate results enabling the most effective patient care. For more about the company, please visit CBLPath.com.

Documents and/or Photos available for this release:
Formatted pdf of press release - Dr. Douglas Gnepp joins CBLPath

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 367300

Contact Information:

Contact:
Tom Curtis
SVP, Marketing
Sonic Healthcare USA fka CBL Path
Phone: (704) 262-6572
E-Mail: tcurtis@sonichealthcareusa.com

Dr. Carlos Urmacher
co-CEO and Chief Medical Officer
CBLPath
Phone: 914.698.5706
E-Mail: curmacher@cblpath.com